MONTREAL, September 12, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, announced today availability on its website of all seven presentations made at the 2017 International Meeting on The Molecular Biology of Hepatitis B Viruses held September 3-7, 2017 in Washington DC (http://www.hbvmeeting.org).
These presentations highlighted recent progress in the development of NAP technology including the following:
A new in vitro model restoring the intracellular transit of NAPs in the HepG2.2.15 cell line that normally occurr in vivo in hepatocytes, restoring the ability of NAPs to selectively block subviral particle secretion in this model system with IC50’s in the nM range (Poster P-146).
In vitro evaluations of NAP activity in HDV infection and new data demonstrating the post entry effects of NAPs observed clinically against HDV infection are derived from direct interactions with the large and small forms of the hepatitis delta antigen (Posters P-144 and P-145).
Analysis of HBsAg quasispecies evolution and mathematical modelling of viral dynamics during NAP treatment in the REP 102 protocol (Posters P-127 and P-148).
A summary of the clinical effects in completed and ongoing clinical trials was presented during the meeting (Poster P-147) and during the Satellite Symposium held on September 7: New HBV Antiviral and Immune Modulatory Therapies in Late Pre-Clinical/Clinical Development (Abstract O-198). These presentations highlighted Replicor’s substantial clinical experience with NAPs as part of advanced combination therapy regimens in different patient populations and demonstrated the reliable and unique ability of NAPs to clear HBsAg in the majority of patients treated. These presentations also highlighted the dramatic improvement in the ability of immunotherapy to restore functional control of HBV infection that persists after therapy is withdrawn when HBsAg levels fall below 1 IU/mL during therapy. All of these presentations are now available at www.replicor.com/science/conference-presentations.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.